Shuttle Pharmaceuticals Holdings, Inc.

SHPH

$3.52

+1.10%

N/A+$0.04

Healthcare

Drug Manufacturers - Specialty & Generic

NASDAQ

Active Trading

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence ...

CEO Profile of SHPH

Christopher Cooper

Shuttle Pharmaceuticals Holdings, Inc.

Tenure 1yKey-man risk: High

Shuttle Pharmaceuticals is a high-risk, clinical-stage entity currently struggling for financial survival. The interim CEO is attempting a turnaround focused on capital markets, but the company's valuation trajectory highlights the...

Key Risk

•Extremely low market capitalization

•Constant need for capital to fund clinical trials

•Significant potential for further shareholder dilution

Key Tailwind

•Focus on specialized radiation oncology niche

•Scientific foundation at recognized academic institutions

Christopher Cooper

Shuttle Pharmaceuticals Holdings, Inc. (SHPH) · NASDAQ

Tenure 1 yearsNon-founder CEOKey-man risk: High

BBA, M.B.A.

Origin Story

Christopher Cooper was appointed Interim Co-CEO in March 2025 to lead capital markets and business strategy for the radiation oncology-focused biopharmaceutical company.

First Break: Insufficient public data available regarding pre-Shuttle career history.

Path to CEO: Christopher Cooper joined Shuttle Pharmaceuticals as an interim Co-CEO in March 2025 alongside founder and Chairman Dr. Anatoly Dritschilo, tasked with sharpening the company's business focus and capital market execution.

Christopher Cooper was brought in during a critical period for the company to provide dedicated focus on capital raising and operational strategy, allowing the company's founder, Dr. Anatoly Dritschilo, to focus on the scientific and clinical trial progress of the firm's radiation-sensitizing oncology therapeutics.

interimcapital marketsbiotech

Investment Take

Key Tailwinds

Focus on specialized radiation oncology niche

Scientific foundation at recognized academic institutions

Key Risks

Extremely low market capitalization

Constant need for capital to fund clinical trials

Significant potential for further shareholder dilution

High reliance on clinical success for survival

Career History

Cooper's career path prior to Shuttle is not publicly documented in detail, but his current appointment reflects an emphasis on financial and business strategy.

financestrategy

Company Performance

The company has faced severe financial and market headwinds, with shares down over 90% in the last year.

Revenue: Early-stage development company with negligible commercial revenue.

Profitability: Consistently negative; reliant on continuous funding to support clinical trials.

Stock: Significant decline of over 92% over the trailing 12 months as of July 2026.

•Significant stock value erosion

•Need for reverse split authorization

clinical-stagemarket-cap-pressure

Management Ability

Management style is currently defined by a dual-leadership structure intended to balance clinical R&D with business survival.

Style: Strategic and focused on corporate survival.

The organizational structure involves a split mandate where the interim CEO manages business development and capital markets while the founder-Chairman oversees the medical and scientific pipeline. This structure is a response to the company's urgent need for liquidity and clinical results.

co-leadershiprestructuring

Capital Allocation

Capital allocation is strictly focused on financing clinical trials to sustain operations.

Extreme focus on capital preservation due to severe liquidity constraints.

The company operates in a cash-burn phase typical of discovery-stage biotech, with management prioritizing survival through potential mergers or ongoing financing rounds. The interim CEO was specifically installed to address these financial hurdles.

cash-burncapital-constrained

Fundraising & Financing

Fundraising is the primary and constant imperative for company management.

Dilution: Significant; the company is actively pursuing measures like reverse splits to maintain market standing.

The company is perpetually seeking funding to finance clinical trials, leading to significant investor dilution concerns. Management is actively soliciting shareholder support for corporate governance measures to enable future financing actions.

dilutionfunding-dependent

Governance & Control

Governance is dominated by the founder, Anatoly Dritschilo, despite the addition of interim executive leadership.

Dr. Anatoly Dritschilo remains Chairman of the Board and a Co-CEO, maintaining significant influence over the company's direction. The structure highlights the high importance of the founder's vision to the company's mission.

founder-influence

Health & Succession

Health and succession status is stable, with no public concerns reported.

Health Status: No public concerns

Key-man Risk: High

High reliance on the original scientific founders; succession for clinical leadership would be significant.

founder-risk

R&D & Tech Vision

The core tech vision is the development of compounds that sensitize cancer cells to radiation therapy.

R&D is the vast majority of the company's operational expenditure.

Radiation-sensitizing oncology therapeutics: Ongoing

Highly specialized focus on radiation oncology; pipeline status is the primary value driver.

The R&D roadmap is focused on long-term clinical trials. The company's scientific leadership attempts to leverage research originating from Georgetown University to create differentiating therapeutic platforms.

radiation-oncologyr&d-intensive

Talent Recruitment

Ability to attract talent is focused on clinical and scientific expertise.

Small, lean team largely comprised of founding scientific members and recently added interim business leadership.

Retention: Mixed, typical of a high-risk clinical-stage biotech.

Management emphasizes the scientific qualifications of its team, particularly the medical and Ph.D. credentials of its founding members, to underpin its clinical development activities.

scientific-bench

Strengths

The CEO's defining strength is a strategic focus on business operations and financial markets during a critical period.

Capital Markets Strategy: Appointed to specifically address the company's critical financial and capital structure challenges.

business-focus

Weaknesses & Failures

Management is struggling with a severe and rapid loss of shareholder value and liquidity.

Stock Performance

Extreme price depreciation over the last 12 months.

Example: Over 90% decline in stock price.

value-destruction

Marketing & Brand

Marketing is focused on building credibility with institutional investors rather than product-based consumer branding.

Brand is synonymous with its clinical-stage radiation-oncology research pipeline.

The brand strategy centers on demonstrating to the scientific and medical community that the company's radiation-sensitizing compounds have high therapeutic potential, while reassuring investors about the path to commercialization.

investor-relationsbiotech-branding

PR & Communication

Communication is transparent regarding the company's operational and clinical progress, despite a challenging stock performance.

Media Reputation: Low profile

Management regularly provides updates through regulatory filings, corporate presentations, and press releases. The communication tone is focused on the scientific milestones of the radiation therapy assets.

regulatory-drivenscientific-focused

Supply Chain of SHPH

Upstream / Downstream / Proxies

Upstream

TCG GreenChem, Inc. (Subsidiary of TCG Lifesciences Pvt. Ltd.)University of Iowa Pharmaceuticals (UI Pharmaceuticals)Theradex Oncology (Theradex Systems Inc.)Georgetown UniversityUniversity of California, San Francisco (UCSF)Molecule.ai (Acquired by SHPH Q4 2025)TCG GreenChem Manufacturing Pvt. Ltd. (India subsidiary of TCG Lifesciences)Propagenix, Inc.

Downstream

None (Pre-Commercial Stage)Georgetown University Medical Center (Clinical Trial Site)Allegheny Health Network (AHN) Cancer InstituteUNC Medical Center / UNC Lineberger Comprehensive Cancer Center

Proxies

Karyopharm Therapeutics Inc.NASDAQ:KPTI Onconova Therapeutics Inc.NASDAQ:ONTX Candel Therapeutics Inc.NASDAQ:CADL

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer